SEC Form 4 · accession 0001104659-15-012181
Bellerophon Therapeutics, Inc. · BLPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martin Meglasson
Officer — Chief Scientific Officer
Period of report
Feb 13, 2015
Accepted (ET)
Feb 19, 2015 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001600132
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $12.00 | Feb 13, 2015 | A | 1,995 | A | — | Feb 12, 2025 | Common Stock | 1,995 | 1,995 | D |
Explanation of responses
- F1This option was granted on February 13, 2015. This option vests as to 25% of the underlying shares on each one year anniversary of the date of grant.